XClose

UCL Cancer Institute

Menu

Cancer Drug Development

Our main research interests lie in cancer drug development, with a particular focus on Hepatocellular Carcinoma (HCC) and Neuroendocrine Tumours (NET).

Group leader

Professor Tim Meyer

Professor of Experimental Cancer Medicine
Research Department of Oncology

Email: t.meyer@ucl.ac.uk

UCL Cancer Institute
Huntley Street
London, WC1E 6BT

UCL Profile

Professor Tim Meyer

Research

I run a specialist clinic in these tumour types at the Royal Free Hospital and an ‘Early-Phase Trial’ Clinic at the NIHR Wellcome UCH Clinical Research Facility (CRF).

In addition to leading an extensive clinical trial portfolio, I have integrated biomarker research into my clinical practice and this has increasingly focused on the role of Circulating Tumour Cell (CTCs) as predictive and prognostic markers of disease.

My current research projects include defining the role of CTCs as pharmacodynamic markers and surrogates for molecular profiling of tumours in the context of drug development.

I am the Cancer Director of the NIHR Wellcome UCH Clinical Research Facility and the Joint Director of the UCL ECMC. Nationally, I Chair the TRANSNET Committee. I am also a member of the UKNETS Steering Committee and I sit on both the Hepatobiliary and NET NIHR Clinical Studies Sub-Groups.

Selected publications

  1. Meyer T, Wendi Q, Caplin ME, et al. Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. European Journal of Cancer 2014; 50, 902– 911
  2. Francis JM, Kiezun A, Ramos AH, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors, Nat Genet. 2013 Dec;45(12):1483-6
  3. Kogelberg H, Miranda E, Burnet J ... Meyer T, et al. Generation and characterization of a diabody targeting the avß6 integrin. PLoS One. 2013 Sep 4;8(9):e73260
  4. Hemmerle T, Probst P, Giovannoni L, Green AJ, Meyer T, Neri D. The antibody-based targeted delivery of TNF in combination with doxorubicin cures sarcomas in mice and confers long lasting protective immunity. Br J Cancer. 2013 Sep 3;109(5):1206-13
  5. Kadalayil L, Benini R, Pallan L ... Meyer T. A simple prognostic scoring system for patients receiving transarterial-embolisation for hepatocellular cancer Annals of Oncology 2013 Oct;24(10):2565-70
  6. Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer. 2013 Mar 14;108(9):1838-45.
  1. Meyer T, Roughton M, Yu D, et al. A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization versus embolization alone for hepatocellular cancer. Br J Cancer 2013 108(6):1252-9
  2. Khan MS, Kirkwood A, Tsigani T ... Meyer T. Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors. J Clin Oncol 2013; 31:365-372
  3. Gillmore R, Stuart S, Kirkwood A ... Meyer T, EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation. J Hepatol 2011; 55 (6):1309-1316
  4. Khan MS, Tsigani T, Rashid M ... Meyer T, Circulating Tumour Cells and EpCAM Expression in Neuroendocrine Tumours. Clin Canc Res 2011; 17(2):337-45
  5. Turner NC, Strauss SJ, Sarker D ... Meyer T. Chemotherapy with 5-Fluorouracil, Cisplatin and Streptozocin (FCiSt) for neuroendocrine tumours. Br J Cancer. 2010, 102(7), pp. 1106-12.